TScan Therapeutics announced a significant strategic reorganization to prioritize its preclinical in vivo solid tumor program and extend its cash runway. The company will pause further enrollment in its Phase 3 ALLOHA-2 study for its heme malignancy candidate (TSC-101) due to capital constraints. The restructuring also includes the termination of its Chief Financial Officer and Chief Medical Officer.
Key Details
- Workforce Reduction: The company is reducing its workforce by approximately 75%, with the reorganization expected to be substantially complete by the end of Q4 2026.
- Financial Impact: TScan expects to incur approximately $4.1 million in employee-related costs but anticipates cumulative cost savings of $55.0 million through the end of 2027. The company's cash runway is now extended into Q4 2027.
- Executive Departures: As of September 2, 2026, Chief Financial Officer Jason A. Amello and Chief Medical Officer Chrystal Louis, M.D., were terminated. CEO Gavin MacBeath has assumed the duties of principal financial officer.
- Nasdaq Notice: The company also disclosed it received a notice from Nasdaq on August 27, 2026, for failing to meet the $1.00 minimum bid price requirement, with an initial 180-day period to regain compliance.